REMARKS

Claim 6 has been amended to correct an inadvertent error in the numbering of sequence identifiers in the claim. Support for the amendment can be found in the sequence listing. The claim recited a *polypeptide* (SEQ ID NO:9) whereas SEQ ID NO:9 is the polynucleotide sequence that encodes the claimed polypeptide. The sequence identifiers in the claim have been changed to SEQ ID NO:10, which is the polypeptide encoded by SEQ ID NO:9. The specification (page 4, paragraphs beginning at line 7 and line 15) has also been amended to correct the same inadvertent errors. .

A document entitled "Version With Markings to Show Changes Made" setting forth a marked-up version of the amended specification and claim is attached hereto.

Entry of this amendment prior to examination of the merits is respectfully requested.

Respectfully submitted,

Dated 24 Oct 2002

By /Talivaldis Cepuritis/
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180

Version With Markings To Show Changes Made

In the Specification:

The paragraph beginning at line 7 on page 4 has been replaced with the following paragraph:

Preferred truncated tryptophanyl tRNA synthetase polypeptides include a polypeptide consisting essentially of amino acid residues 48-471 of SEQ ID NO:~~9~~10; a polypeptide consisting essentially of amino acid residues 71-471 of SEQ ID NO:~~9~~10; a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO:910 with polymorphonuclear leucocyte elastase; and fragments thereof comprising the amino acid sequence -Asp-Leu-Thr-. In one preferred embodiment, the truncated tRNA synthetase polypeptide is mammalian, and more preferably, human.

The paragraph beginning at line 15 on page 4 has been replaced with the following paragraph:

In another embodiment, the invention comprises an isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of a polynucleotide of SEQ ID NO:9, a polynucleotide which is hybridizable to a polynucleotide of SEQ ID NO:9, a polynucleotide encoding a truncated tryptophanyl-tRNA synthetase polypeptide which includes a Rossmann fold nucleotide binding domain, a polynucleotide that is hybridizable to a polynucleotide encoding a truncated tryptophanyl-tRNA synthetase polypeptide which includes a Rossmann fold nucleotide binding domain, a polynucleotide encoding a polypeptide mentioned in the preceding paragraph, a polynucleotide that is hybridizable to a polynucleotide encoding a polypeptide mentioned in the preceding paragraph, a polynucleotide encoding a polypeptide epitope of SEQ ID NO:910, and a polynucleotide that is hybridizable to a polynucleotide encoding a polypeptide epitope of SEQ ID NO:910. In a preferred embodiment the invention comprises a recombinant expression

vector comprising the isolated nucleic acid molecule of encoding a tRNA synthetase polypeptide. Another embodiment is a host cell comprising a recombinant expression vector comprising the isolated nucleic acid molecule of SEQ ID NO:9 encoding a tRNA synthetase polypeptide.

In the Claims:

Claim 6 has been amended to read:

6. (amended) The isolated polypeptide of claim 1, wherein the truncated tRNA synthetase polypeptide is a member of the group consisting of

a polypeptide consisting essentially of amino acid residues 48-471 of SEQ ID NO:910;

a polypeptide consisting essentially of amino acid residues 71-471 of SEQ ID NO:910;

a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO:910 with polymorphonuclear leucocyte elastase; and

fragments thereof comprising the amino acid sequence

-Asp-Leu-Thr-.--